Eli Lilly & Company — Weekly Profile
A QBH investor briefing on Lilly’s obesity/diabetes flywheel, Alzheimer’s franchise, acquisition strategy and the policy battles shaping GLP-1 and insulin economics.
Company Snapshot
- Name: Eli Lilly & Company.
- Ticker: LLY (NYSE).
- Sector: Global pharmaceuticals & biotech with anchor franchises in diabetes/obesity, neuroscience, oncology and immunology.
- HQ: Indianapolis, Indiana.
- Flagship brands: Mounjaro & Zepbound (GLP-1/GIP incretins), Verzenio (CDK4/6+ breast cancer), Kisunla (donanemab for early Alzheimer’s), Jardiance (SGLT2 cardiometabolic, co-promoted), Taltz (immunology), Omvoh & Ebglyss (IBD/derm) plus a large legacy diabetes and insulin franchise.
Why This Company Now (weekly hook)
Lilly has become the reference name for obesity and cardio-metabolic medicine: GLP-1 incretin drugs are now a double-digit percentage of S&P 500 earnings growth. Q3 2025 results showcased how the company is recycling that cash flow into Alzheimer’s, gene editing, radiopharma and AI-driven discovery, while wrestling with political scrutiny on pricing, access and coverage.
What Changed Recently (news, filings, policy)
- Q3 2025 “incretin blowout”: Revenue climbed to about $17.6B (+54% YoY), driven by Mounjaro $6.5B (+109% YoY) and Zepbound $3.6B (+~185% YoY). Full-year 2025 revenue guidance was raised to roughly $63–63.5B.
- Alzheimer’s franchise scaling: Kisunla (donanemab) is now approved in the U.S., Australia, China and the EU for early symptomatic Alzheimer’s. A July 2025 FDA label update softened ARIA-E risk via a gentler titration schedule, while preserving plaque clearance.
- Dealmaking in oncology & cardiometabolic: Lilly completed the acquisition of Verve Therapeutics (PCSK9 one-and-done gene editing for cardiovascular disease), agreed to acquire Scorpion’s STX-478 PI3Kα inhibitor in breast cancer, and continues integrating POINT Biopharma (radioligands) and Morphic (oral integrins for IBD).
- AI & small-molecule obesity bets: A $1.3B collaboration with Superluminal Medicines gives Lilly AI-designed GPCR modulators for obesity and cardiometabolic disease, while a separate partnership with Nvidia is building an in-house AI supercomputer to accelerate drug discovery and manufacturing analytics.
- Policy & litigation backdrop: Lilly has cut insulin list prices by ~70% and capped out-of-pocket insulin at $35/month, including in a Minnesota settlement, but faces ongoing Texas litigation around historical insulin pricing and alleged GLP-1 marketing kickbacks, which it contests. CMS has meanwhile declined broad Medicare coverage for GLP-1 weight-loss use, keeping obesity reimbursement a live political fight.
Earnings & Operating Highlights (Q3 2025 lens)
- Q3 2025 revenue: ≈ $17.6B, up ~54% YoY, with growth almost entirely volume-driven rather than price.
- Mounjaro (tirzepatide, T2D): ≈ $6.5B sales in Q3 2025, +109% YoY; ex-U.S. revenue more than tripled as new markets launched.
- Zepbound (tirzepatide, obesity/OSA): ≈ $3.6B in Q3 2025, +~185% YoY, now rolling out across Europe and big-box retail channels in the U.S.
- Verzenio (abemaciclib): ≈ $1.47B in Q3 2025, +~7% YoY, still growing off an adjuvant breast-cancer label.
- 2025 trajectory: Q1 revenue (~$12.7B, +45% YoY) and Q2 (~$15.6B, +38% YoY) set up a full-year guide of roughly $63–63.5B, dominated by incretin products.
Growth Engines: Product-Level Snapshot
- Incretin franchise (Mounjaro + Zepbound): Dual GIP/GLP-1 agonist tirzepatide underpins both brands. Mounjaro is indicated for type 2 diabetes; Zepbound for obesity and, more recently, moderate-to-severe obstructive sleep apnea in adults with obesity. The pair are now a large minority of Lilly revenue and anchor capex and M&A capacity.
- Orforglipron (oral GLP-1): A once-daily small-molecule GLP-1 agonist that has produced strong Phase 3 data in type 2 diabetes and obesity. Lilly has pointed to regulatory filings in the near term and potential launch as the first mass-market oral GLP-1 in its portfolio.
- Neuroscience — Kisunla (donanemab): Monthly IV amyloid-targeting antibody for early symptomatic Alzheimer’s. Phase 3 data showed up to ~35% slowing of cognitive decline vs placebo, with a finite-duration treatment paradigm once amyloid plaques are cleared. Global label work (including updated titration in the U.S.) is focused on reducing ARIA risk while preserving plaque removal.
- Oncology — Verzenio, STX-478 & radioligands: Verzenio continues to expand in high-risk breast cancer. The Scorpion deal brings STX-478, a mutant-selective PI3Kα inhibitor, into the pipeline to potentially pair with endocrine therapy. The completed POINT Biopharma acquisition adds radioligand therapies for solid tumors.
- Immunology & IBD — Morphic, Taltz, Omvoh: Taltz remains a growth driver in psoriasis and psoriatic arthritis. The Morphic transaction adds oral α4β7 integrin inhibitors (e.g., MORF-057) in Phase 2 for ulcerative colitis and Crohn’s, supporting a deeper IBD portfolio alongside Omvoh.
- Cardiometabolic gene editing — Verve Therapeutics: Through the Verve acquisition Lilly gains VERVE-102 and related in vivo CRISPR programs targeting PCSK9 and ANGPTL3, aimed at one-time gene editing to permanently lower LDL and triglyceride-rich lipoproteins in high-risk patients.
Top Growth Drivers (Product Grid)
Not a full product list — focus is on where incremental cash flow and R&D energy are concentrated as of late 2025.
Jump to policy & politics or skip down to the GLP-1 vs rest chart.
Margin & Efficiency Notes
Incremental margins on the GLP-1 franchise are high: small-molecule manufacturing and fill-finish bottlenecks are being addressed with a multi-site capex program (new plants in the U.S. and Europe) and heavy use of contract manufacturers. Management has repeatedly flagged capacity as the main near-term constraint on GLP-1 revenue, not demand.
Non-incretin businesses (Verzenio, Taltz, Jardiance and newer oncology/radiopharma assets) provide diversification and help soften any future pricing or coverage shocks to obesity and diabetes drugs.
Balance Sheet, Capex & AI Infrastructure
- Balance sheet: While not as cash-loaded as a Berkshire-style conglomerate, Lilly’s GLP-1 cash flows and high-margin profile support an active M&A and capex program.
- Manufacturing build-out: Management has committed to multibillion-dollar investments in new GLP-1 manufacturing and device-fill sites to ease supply constraints and support global rollout.
- AI supercomputing: The Nvidia partnership layers an in-house AI supercomputer (Blackwell-class GPUs) onto existing R&D and manufacturing analytics, aimed at faster target discovery, simulation and trial optimization.
Capital Allocation & Deal Pattern
- M&A tilt: Lilly is targeting platform-style assets (gene editing, radioligands, oral integrins, GLP-1-adjacent biology) rather than late-stage “me-too” drugs. Verve, POINT, Morphic, Sigilon and Versanis are emblematic of this approach.
- Strategic collaborations: Superluminal (GPCR small molecules), Nvidia (AI infra) and various obesity-pipeline alliances indicate continued willingness to partner where platforms and talent are scarce.
- Shareholder returns: Historically via dividends and selective buybacks; in the current GLP-1 investment phase, emphasis has shifted toward capex and acquisitions over large repurchase programs.
Policy, Pricing & Political Backdrop
After years of criticism over insulin prices, Lilly announced ~70% list-price cuts for key insulins and capped patient out-of-pocket costs at $35/month via the Insulin Value Program. State-level settlements, notably in Minnesota, now lock in $35/month insulin pricing and require donations of free insulin to safety-net clinics for several years, turning a political liability into a partial reputational repair.
Obesity-only use of GLP-1 drugs (e.g., Zepbound) remains outside Medicare Part D coverage, even as these medicines gain additional cardiometabolic indications. At the same time, Texas has sued Lilly and others over historical insulin pricing and alleged kickback-like GLP-1 support services for prescribers—cases Lilly disputes. The political risk is less about current GLP-1 demand and more about future price controls, rebate structures and coverage mandates.
ESG & Access Notes
- Access & pricing: Insulin price moves and patient-assistance programs are central to Lilly’s “access” narrative and will remain under scrutiny as GLP-1 profits soar.
- Neuro & safety: Kisunla label updates targeting ARIA risk show a willingness to iteratively de-risk high-profile neuro assets while collecting real-world safety data.
- Cardiometabolic burden: Strategically, Lilly frames obesity and diabetes as global health-system cost drivers, positioning weight-loss drugs and cardiometabolic gene editing as long-run cost-savers rather than just “lifestyle” medicines.
Chart of the Week: GLP-1 vs Everything Else (illustrative)
Description: Illustrative bar chart comparing year-to-date 2025 revenue from Mounjaro + Zepbound versus the rest of Lilly’s portfolio. Exact mix will move each quarter; this is meant as an executive-level sense of concentration risk and cash-flow firepower.
TL;DR & The Future
Bottom line: Lilly has become the canonical GLP-1 and obesity platform, but is behaving like a diversified “pharma compounder” rather than a pure weight-loss trade. Watch: (1) GLP-1 capacity and reimbursement in the U.S. and Europe, (2) real-world Kisunla uptake and payer decisions, (3) execution on Verve, Scorpion, Morphic and radioligand pipelines, and (4) any structural move in U.S. drug-pricing policy that hits high-gross-margin franchises first.
Disclaimer: This page is for information and education only. It is not investment, medical or legal advice. Always do your own research and consult qualified professionals before making health or financial decisions.